HOMEPostContact Us
Posted November 05. 2013 12:54PM

Dartmouth prof’s biomed firm follows a more entrepreneurial path for its anti-cancer discovery

Click headline or here to open angled item
Officially launched in 2011, ImmuNext has already landed what could potentially be a $150 million deal with Johnson & Johnson that takes the company’s cancer-fighting technology from lab to fruition